PubMed HealthSearch

PubMed · 1858309

Exaggerated warfarin sensitivity: a case report.

Abstract

A 64-y-old male was hospitalized because of significant bleeding and a prolonged prothrombin time (PT) (greater than 200 sec) following an inadvertent doubling of his anticoagulant dose. He was previously well controlled on 2.5 mg warfarin every fourth day. Treatment included vitamin K, fresh frozen plasma, and packed red blood cells. Warfarin plasma concentrations, clotting factor analysis (CFA) and PTs were analyzed to evaluate this patient. Following hospitalization, the patient was followed by the Anticoagulation Clinic and his dose was stabilized at 0.5 mg daily. He experienced no further bleeding episodes and his PT ratio was maintained at 1.5 times control. The response to a dose of warfarin varies greatly from patient to patient. Previous reports of abnormal responses to warfarin can be categorized as either warfarin "resistant" or "sensitive." The preponderance of reports are compliance or hereditary warfarin resistance. This patient represents a case of exaggerated warfarin sensitivity that cannot be easily explained. There was no evidence of a drug interaction, warfarin concentrations were not excessive, and CFA was reflective of a moderate warfarin effect. Extreme tissue sensitivity to warfarin is a plausible explanation for this abnormal response.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G J Vanscoy, J W McAuley. 1991. Exaggerated warfarin sensitivity: a case report.. https://pubmed.ncbi.nlm.nih.gov/1858309/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.

Platelet clots resist fibrinolysis by plasminogen activators. We hypothesized that platelet factor XIII may enhance the fibrinolytic resistance of platelet-rich clots by catalyzing the crosslinking of alpha 2-antiplasmin (alpha 2AP) to fibrin. Analysis of plasma clot structure by polyacrylamide gel electrophoresis and immunoblotting revealed accelerated alpha 2AP-fibrin crosslinking in platelet-rich compared with platelet-depleted plasma clots. A similar study of clots formed with purified fibrinogen (depleted of factor XIII activity), isolated platelets, and specific factor XIII inhibitors indicated that this accelerated crosslinking was due to the catalytic activity of platelet factor XIII. Moreover, when washed platelets were aggregated by thrombin, there was evidence of platelet factor XIII-mediated crosslinking between platelet alpha 2AP and platelet fibrin(ogen). Specific inhibition (by a monoclonal antibody) of the alpha 2AP associated with washed platelet aggregates accelerated the fibrinolysis of the platelet aggregate. Thus in platelet-rich plasma clots, and in thrombin-induced platelet aggregates, platelet factor XIII actively formed alpha 2AP-fibrin crosslinks, which appeared to enhance the resistance of platelet-rich clots to fibrinolysis.

Blood Coagulation Factors